Limits...
Prognostic value of Ezrin in solid tumors: a meta-analysis of the literature.

Han K, Qi W, Gan Z, Shen Z, Yao Y, Min D - PLoS ONE (2013)

Bottom Line: Several databases were searched, including Pubmed, Embase and Cochrane databases.The endpoints were overall survival (OS), progression-free survival (PFS).So large well-designed prospective studies are now needed to confirm the clinical utility of Ezrin as an independent prognostic marker.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Shanghai Sixth People's Hospital East Campus, Shanghai Jiao Tong University, Shanghai, China.

ABSTRACT

Purpose: Ezrin is a cytoskeletal protein involved in tumor growth and invasion. However its prognostic value for survival in patients with solid tumor remains controversial.

Methods: Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.

Results: Twenty-seven eligible trials involving 4693 patients were ultimately identified. A summary hazard ratio (HR) of all studies and sub-group hazard ratios were calculated. The combined HR suggested that a positive Ezrin expression had an impact on overall survival (OS) [1.95, 95% confidence interval (CI) 1.60-2.39; P<0.001] in all eligible studies and progress free survival (PFS): (2.30 95% CI 1.0-3.61; P = 0.001). Similar results were also observed in subgroup analysis, according to tumor types, regions, patients' number and publication year.

Conclusions: Our findings suggested that Ezrin protein expression might be a factor for a poor prognosis in patients with solid tumor. So large well-designed prospective studies are now needed to confirm the clinical utility of Ezrin as an independent prognostic marker.

Show MeSH

Related in: MedlinePlus

Egger's test result of OS.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3716773&req=5

pone-0068527-g005: Egger's test result of OS.

Mentions: NoevidenceofpublicationbiaswasdetectedfortheHR of OS and PFS in this studybyeitherBeggorEgger'stest(HRofOS:Begg'stestp = 0.085,Egger'stestp = 0.455;HR of PFS: Begg'stestp = 0.293,Egger'stestp = 0.764) (Fig. 4 and Fig. 5).


Prognostic value of Ezrin in solid tumors: a meta-analysis of the literature.

Han K, Qi W, Gan Z, Shen Z, Yao Y, Min D - PLoS ONE (2013)

Egger's test result of OS.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3716773&req=5

pone-0068527-g005: Egger's test result of OS.
Mentions: NoevidenceofpublicationbiaswasdetectedfortheHR of OS and PFS in this studybyeitherBeggorEgger'stest(HRofOS:Begg'stestp = 0.085,Egger'stestp = 0.455;HR of PFS: Begg'stestp = 0.293,Egger'stestp = 0.764) (Fig. 4 and Fig. 5).

Bottom Line: Several databases were searched, including Pubmed, Embase and Cochrane databases.The endpoints were overall survival (OS), progression-free survival (PFS).So large well-designed prospective studies are now needed to confirm the clinical utility of Ezrin as an independent prognostic marker.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Shanghai Sixth People's Hospital East Campus, Shanghai Jiao Tong University, Shanghai, China.

ABSTRACT

Purpose: Ezrin is a cytoskeletal protein involved in tumor growth and invasion. However its prognostic value for survival in patients with solid tumor remains controversial.

Methods: Several databases were searched, including Pubmed, Embase and Cochrane databases. The endpoints were overall survival (OS), progression-free survival (PFS). The pooled hazard ratio (HR) or odds ratio (OR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.

Results: Twenty-seven eligible trials involving 4693 patients were ultimately identified. A summary hazard ratio (HR) of all studies and sub-group hazard ratios were calculated. The combined HR suggested that a positive Ezrin expression had an impact on overall survival (OS) [1.95, 95% confidence interval (CI) 1.60-2.39; P<0.001] in all eligible studies and progress free survival (PFS): (2.30 95% CI 1.0-3.61; P = 0.001). Similar results were also observed in subgroup analysis, according to tumor types, regions, patients' number and publication year.

Conclusions: Our findings suggested that Ezrin protein expression might be a factor for a poor prognosis in patients with solid tumor. So large well-designed prospective studies are now needed to confirm the clinical utility of Ezrin as an independent prognostic marker.

Show MeSH
Related in: MedlinePlus